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compare the effectiveness with CAS and CEA in 677 patients with symptomatic 
carotid artery stenosis in korean clinical practice. Methods: From January 1 2008 
to December 31 2011, retrospective cohort study was conducted in 677 symptomatic 
carotid stenosis patients with more than 50% stenosis) (CAS= 346, CEA= 331) in the 
Korean hospitals (Asan medical center, Samsung medical center, Severance hospital, 
Inha university hospital, Chonnam university hospital). The primary outcome was 
stroke, myocardial infarction, or death during periprocedural (30-day) and postproce-
dural period. Results: For 677 patients over 2-year follow-up period, All death, major 
stroke, minor stroke were higher in CAS group than CEA (1.45% vs. 0.30%, 4.05% vs. 
1.81%, 3.47% vs. 3.02%, 0.58% vs. 0%). All outcomes were higher in CAS than in CEA 
within 30-day after treatment and in subsequent years, except the incidence of 30 
days-minor stroke. ConClusions: CEA was superior to CAS in symptomatic patients 
with carotid stenosis. This study suggests that CEA can be considered the first-line 
therapy for symptomatic carotid artery stenosis in South Korea.
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Real-Time assessmenT Of mediCaTiOn Taking and aCTiViTies Of daily 
liVing in PaTienTs WiTh UnCOnTROlled hyPeRTensiOn
DiCarlo L., Kim Y.A., Young J, Bezhadi Y.
Proteus Digital Health, Redwood City, CA, USA
objeCtives: For patients with uncontrolled hypertension, differentiation of phar-
macological resistance from inadequate or improper medication use is key to clini-
cal management. Proteus Digital Health has developed a unique digital feedback 
system, which utilizes an Ingestible Sensor (IS) to determine medication-taking 
patterns. A wearable sensor in the form of an adhesive patch collects timing and 
taking of IS ingestions, and physiological and behavioral metrics such as heart 
rate, and patterns of activity and rest, providing insights into the patient’s day-
to-day lifestyle. This study evaluates the utility of the Proteus system in patients 
with uncontrolled hypertension. Methods: Patients with a history of uncontrolled 
hypertension (BP> 140/90) at 5 primary care centers in the United Kingdom were 
prescribed the Proteus system for 14 days. Patients co-ingested the IS along with 
their prescribed BP medications while simultaneously wearing the patch. BP was 
measured on days 1 and 14 by a clinician, and all other parameters, such as adher-
ence, activity and rest patterns, were collected via the Proteus system. Results: 
Of the 190 patients, 21 patients had incomplete data. In the remaining 169 patients 
(89%), mean medication adherence was 88%, and mean BP decrease was -7.6 mm 
Hg systolic and -3.8 mm Hg diastolic. The system data provided diagnostic insight 
differentiating non-response vs. non-adherence. One hundred forty-eight (78%) 
patients had ≥ 70% adherence; 100 (53%) achieved blood pressure control on their 
prescribed therapy, and 48 (25%) remained uncontrolled and required modifica-
tion of their therapeutic regimen. The remaining 21 patients (11%) were identi-
fied as needing intervention to support medication adherence. ConClusions: In 
patients with a history of uncontrolled hypertension, 53% achieved BP control within 
2 weeks, and 25% received an informed therapeutic intervention using the Proteus 
system. Thus, Proteus can identify specific individual needs for progressing through 
the recommended treatment pathway and for advancing toward treatment goals.
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Use Of COmPUTeR simUlaTiOn TO geneRaTe eVidenCe TO aid healTh 
CaRe deCisiOn making: an examPle Using The aRChimedes mOdel TO 
COmPaRe ROsUVasTaTin WiTh aTORVasTaTin
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objeCtives: Randomized controlled trials (RCTs) provide the most robust evi-
dence source for making patient health care decisions. When RCT data are lacking, 
however, complementary evidence sources may also be needed. As an example of 
this, three clinical trials comparing rosuvastatin with atorvastatin were simulated 
using the Archimedes model, a validated, individual-based simulation of human 
pathophysiology and behaviours, treatment interventions and health care sys-
tems. Methods: Comparison A assessed clinical outcomes in patients receiving 
available doses of the two drugs. Comparison B assessed the impact of initial treat-
ment decisions, with individuals randomized to receive various doses of either 
rosuvastatin or atorvastatin and eligible for treatment intensification for up to 5 
years if target lipid levels were not met. Comparison C assessed the effect of switch-
ing patients’ treatment from rosuvastatin to atorvastatin. Results: In comparison 
A, rosuvastatin was estimated to result in greater reductions than atorvastatin 
in major adverse cardiac events (MACEs) at 5 and 20 years at all doses examined 
(relative risk [RR]: 0.907,0. 892 and 0.931 at 20 years for rosuvastatin 20 mg versus 
atorvastatin 40 mg, rosuvastatin 40 mg versus atorvastatin 80 mg, and rosuvastatin 
20 mg versus atorvastatin 80 mg, respectively; P< 0.05 in all cases). In comparison 
B, outcomes were significantly better in patients initially prescribed rosuvastatin 
relative to atorvastatin (RR of MACE at 10 years: 0.919; P< 0.001). In comparison C, 
risk of MACE was significantly greater in patients who switched from rosuvastatin to 
atorvastatin, relative to those who remained on rosuvastatin (RR at 10 years: 1.115; 
P< 0.001). ConClusions: In this example using the well-validated Archimedes 
model, better outcomes were predicted in patients receiving rosuvastatin than 
in those receiving atorvastatin in a variety of different settings. This provides an 
example of the utility of robust modelling approaches to generating evidence that 
is not available from clinical trials.
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stances. All 3 economic studies found MIS in the treatment of ICH was associated 
with lower costs compared to MM or CR. In one study MIS resulted in a $USD44,329 
saving in acute care costs compared to MM, primarily driven by lower hospital bed 
days (70 vs. 98.9 days). ConClusions And iMPliCAtions oF KeY FindinGs: MIS 
in the treatment of ICH presents convincing evidence for improved efficacy over MM 
and CR. The latest clinical practice guidelines for the treatment of ICH do not yet accu-
rately reflect these latest findings and as such, current treatment practices may be 
lagging behind what the highest level of evidence suggests should be standard of care.
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PhaRmaCOeCOnOmiC gROUnding Of Using POlyPill amlOdiPine WiTh 
aTORVasTaTin VeRsUs mOnOdRUgs in PaTienTs WiTh hyPeRTensiOn and 
dysliPidemia in UkRaine
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objeCtives: One reason of the low efficiency of cardiovascular diseases (CVD) 
treatment in Ukraine is the low adherence of patients. Modern trends improving 
the quality of treatment and increase patients compliance is use of polypills (PP). 
The aim: pharmacoeconomic assesment the feasibility of PP amlodipine and ator-
vastatin versus monodrugs in patients with hypertension and dyslipidemia (DYS) 
from the Ukrainian perspectives point of view. Methods: The results of clinical 
studies AVALON (Granger C. B., McMurray J. J., Yusuf S. et al., 2003) were used. Cost 
minimization analysis of three regimens of patients treatment with hypertension 
and DYS during 8 weeks: PP amlodipine 5 mg + atorvastatin 10 mg; amlodipine 5 mg; 
atorvastatin 10 mg. Results: The results of the clinical research AVALON found, 
that the use of PP amlodipine+atorvastatin provides significant clinical benefit: 
the largest number of patients reached target levels of blood pressure (BP) and 
low-density lipoprotein cholesterol (LDL-C) (45.5%), versus amlodipine (8.3%), ator-
vastatin (28.6%), placebo (3.5%). The scheme using amlodipine is the most expensive 
(cost for course of treatment (CCT) € 20.28), the regimen of atorvastatin 10 mg (CCT 
€ 10.46) and the PP amlodipine+atorvastatin (CCT € 17.72) are less costly. This PP is 
more cost effective versus amlodipine monotherapy (CER = € 38.95 versus € 244.34 
per patient with target levels of BP and LDL-C) and less cost effective compared 
atorvastatin monotherapy (CER = € 36.57 per patient with target levels of BP and 
LDL-C). The cost of an additional unit of effectiveness (ICER) showed that the use of 
PP amlodipine+atorvastatin instead amlodipine provides for the treatment of each 
100 patients additional 37.2 patients achieved target levels of BP and LDL-C and 
saving € 6.88 per patient. ConClusions: Pharmacotherapy of patients with hyper-
tension and DYS based on PP amlodipine+atorvastatin provides significant clinical 
benefit versus monodrugs and pharmacoeconomic advantages versus amlodipine.
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lifeTime CliniCal eVenTs aVOided and ResOURCe UTilizaTiOn WiTh 
aPixaban COmPaRed TO lOW-mOleCUlaR-WeighT hePaRin fOllOWed 
by a ViTamin k anTagOnisT fOR The TReaTmenT and PReVenTiOn Of 
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objeCtives: The AMPLIFY trial compared apixaban to low-molecular-weight 
heparin (LMWH) followed by a vitamin K antagonist (VKA) for treatment and 
prevention of recurrent venous thromboembolism (VTE). The AMPLIFY-EXT trial 
compared extended treatment with apixaban to placebo in previously treated 
patients. This analysis evaluated the potential lifetime implications of apixaban 
treatment versus LMWH/VKA. Methods: A Markov model was developed to eval-
uate the lifetime impact of treatment and prevention of VTE with apixaban (5 mg 
BID for 6 months, then 2.5 mg BID) versus LMWH/VKA. Clinical event rates were 
taken from AMPLIFY, AMPLIFY-EXT, and indirect treatment comparison. Length 
of stay for hospitalizations was taken from AMPLIFY for recurrent VTE (median 
5 days for apixaban, 6 days for LMWH/VKA) and major bleeds (median 5 days for 
apixaban, 7 days for LMWH/VKA). Sixty percent of patients with recurrent VTE 
and all patients with major bleeding were assumed to be hospitalized. Outcomes 
evaluated were events and hospital bed days avoided, number needed to treat to 
avoid a recurrent VTE, number needed to treat to harm with an additional bleed, 
and life years gained. Results: In a cohort of 1,000 patients, lifetime treatment 
with apixaban versus LMWH/VKA resulted in 6 fewer recurrent VTE events, 191 
fewer major bleeds, 707 fewer clinically relevant non-major bleeds, and 1,730 hos-
pital bed days avoided. On average, a patient treated with apixaban gained about 3 
months of life expectancy due to avoidance of VTE events and major bleeds. These 
results translated to one recurrent VTE event avoided for each 157 patients treated 
and one major bleed avoided for each 5 patients treated with apixaban versus 
warfarin. ConClusions: Apixaban for treatment and prevention of VTE appears 
to be a superior alternative to LMWH/VKA, leading to fewer recurrent VTEs, bleed-
ing events, and hospital bed days resulting in a projected increase in life-expec-
tancy.
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objeCtives: Carotid endarterectomy (CEA) has been recommended as the gold 
standard for the management of carotid disease in many clinical guidelines. But, 
in Korean clinical practice, carotid artery stening (CAS) was conducted more than 
CEA (21.6%) based on the national claims-data. The purpose of this study was to 
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Antiplatelets-30%. ConClusions: CHA2DS2-VASc showed better prediction than 
CHADS2 for stroke risk prediction. Dabigatran was observed to have better out-
come followed by VKA and Anti-platelets.
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objeCtives: To evaluate the management of Chronic Thromboembolic Pulmonary 
Hypertension (CTEPH) in a referral hospital by assessing clinical variables, patient-
reported outcomes and caregivers’ burden. Methods: An observational, retrospec-
tive study was conducted. All patients (aged > 18 years) attending the specialised 
unit on CTEPH at the 12 de Octubre Hospital (Spain), between January 2010 and 
November 2012, were offered to participate. Clinical variables were recorded at 
the clinical session for treatment decision (Pulmonary endarterectomy –PEA- if 
operability was confirmed or medication therapy –MT- if inoperable), and after 
one year. Outcomes considered: The New York Heart Association Functional Class 
(FC), 6-Minute Walking Distance, pulmonary arterial pressure, pulmonary vascular 
resistance and pro-brain natriuretic peptide. Participants completed the EQ-5D and 
caregivers’ fulfilled the Zarit Burden Interview. Differences between groups were 
studied (Chi-squared, Mann-Whitney U and ANCOVA). Results: A total of 64 CTEPH 
cases (57.8% males) were included. Mean (SD) age at diagnosis was 55.8 (14.9) and 
67.2% had an III-IV FC at diagnosis. At the moment of treatment prescription, dif-
ferences in clinical variables were not found (all p> 0.4) between PEA (n= 35-54.7%-) 
and MT groups (n= 29-45.3%-). After 12 months, 8 patients died (2 in PEA group and 
6 in MT). Among survivors, FC was significantly better in PEA group (93.9% improved 
at least one level). Regarding EQ-5D, patients undergoing PEA showed significant 
higher utilities (0.83-0.17- vs. 0.53-0.31-p= 0.007) and VAS values (80.22-14.24- vs. 
49.47-20.68-p< 0.001). Furthermore, mean VAS values in PEA group were comparable 
to general population (adjusted by sex and age). Finally, formal care was needed 
by just 4.8% of patients in PEA versus 33.3% in MT. Reported caregivers’ burden 
were relatively low in both groups (p= 0.87). ConClusions: The positive outcomes 
obtained, especially in those patients undergoing PEA, suggest the experienced 
management of CTEPH by this referral hospital and highlights the importance of 
detecting candidates for PEA.
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objeCtives: Few studies have assessed the real-life impact of secondary prevention 
drugs on all-cause mortality post-myocardial infarction (MI), especially in countries 
with low incidence of MI. The objective of this interim analysis after 3.5-year of follow-
up was to assess the real-life all-cause mortality impact of drugs reimbursed for 
MI secondary prevention in France: acetylsalicylic acid (ASA), anti-platelet agents 
(APA), beta-blockers (ß-), angiotensin converting enzyme inhibitors (ACEI), statins, and 
omega-3 supplementation (Om3). Methods: Cohort study of patients with recent 
(≤ 3 months) acute MI included by hospital and non-hospital cardiologists, with 6-year 
follow-up. Vital status was obtained from the National death registry, and failing that 
by patient/relatives/physicians investigation. Drug exposure was defined using both 
physician and patient reports at inclusion. Cox proportional hazard model was used 
to estimate for each drug, mortality hazard ratio (HR) of exposed versus non exposed 
patients, adjusted for gender, age, cardiovascular risk factors, other MI prevention 
drugs, and propensity score to be exposed at inclusion. Results: Between May 2006 
and June 2009, 596 physicians included 5538 patients: mean age 62.1 years, 77.6% male, 
9.6% current smokers, 14.5% diabetic, 44.6% hypercholesterolemic, 43.6% hyperten-
sive, 8.2% with LVEF < 40%. At inclusion, 97.5% were exposed to ASA, 91.0% to APA, 
89.7% to ß-, 71.1% to ACEI, 92.0% to statins, and 15.7% to Om3. The 3.5-year mortality 
was 7.8% (95%CI [7.1%-8.5%]) with an incidence rate of 23.2 per 1000 patient-years. 
Adjusted HR were: 0.98 [0.60-1.61] for ASA, 0.86 [0.60-1.24] for APA, 0.84 [0.63-1.11] 
for ß-, 0.80 [0.61-1.03] for ACEI, 0.67 [0.45-1.00] for statins, and 0.82 [0.58-1.16] for 
Om3. ConClusions: The 3.5 year interim all-cause real-life death reduction point 
estimates were close to those of large randomized controlled trials, except for ASA, 
for which almost all patients were exposed. The study’s statistical power will be suf-
ficient to confirm or not these trends at the final 6-year analysis.
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a daTabase analysis Of PaTienTs eligible fOR seCOnd-line liPid-
lOWeRing TReaTmenT fOR hyPeRChOlesTeROlaemia in england
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objeCtives: In 2012, the NHS Health and Social Care Information Centre (HSCIC), 
with support from NICE, reported on the eligible population for ezetimibe as a 
second-line lipid-lowering therapy (LLT) in England. Several populations were 
omitted from this analysis, including some very high-risk Type 2 Diabetes Mellitus 
(T2DM) patients with CVD. We re-evaluated the eligible population for ezetimibe 
indicated for treatment intensification in a retrospective analysis. Methods: 
Patients with ≥ 1 total cholesterol (TC) measure in each year of interest were iden-
objeCtives: To critically appraise the published network meta-analyses (NMAs) 
evaluating the efficacy or safety of the new oral anticogulants (NOACs) dabigatran, 
rivaroxaban and apixaban for the prevention of stroke in patients with non-valvular 
atrial fibrillation (AF). Methods: A systematic literature review was performed to 
identify the relevant NMAs using MEDLINE®, EMBASE®, Cochrane Library, Database 
of Abstracts of Reviews of Effects, and Health Technology Assessment. The synthesis 
studies were evaluated using the ‘Questionnaire to assess the relevance and cred-
ibility of the NMA’. Results: Eleven NMAs evaluating NOACs among adults with 
non-valvular AF were identified. Most NMAs included three large phase III RCTs, 
comparing NOACs to adjusted-dose warfarin (RE-LY, ROCKET-AF, ARISTOTLE). The 
main differences identified related to potential treatment effect modifiers regard-
ing the mean time spent in therapeutic range (TTR) in the warfarin arm, the risk of 
stroke or systemic embolism across the trials (mean CHADS2 score: Cardiac failure, 
Hypertension, Age ≥ 75 years, Diabetes mellitus, Stroke, 2 two points for stroke) or 
primary versus secondary prevention, and type of populations used in the analysis. 
Kansal et al. appropriately adjusted the ROCKET-AF TTR to match the RE-LY popula-
tion based on individual patient data. Meta-regressions are not expected to mini-
mize confounding bias given limited data, whereas subgroup analyses had some 
impact on the point estimates for the treatment comparisons. ConClusions: 
Results of the synthesis studies were generally comparable and suggested the 
NOACs had similar efficacy, although some differences were identified depending 
on the outcome. The extent to which the differences in the distribution of TTR, 
CHADS2 or primary versus secondary prevention biased the results remains unclear.
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objeCtives: To examine recommended target levels of low-density lipoprotein 
cholesterol (LDL-C) for hyperlipidaemia patients at high risk (i.e., with two or more 
risk factors or coronary heart disease or its risk equivalents) for cardiovascular dis-
ease (CVD); to determine the proportions of patients who do not achieve targeted 
LDL-C levels in real-world setting studies. Methods: A targeted literature review 
identified guidelines and real-world studies that analysed hyperlipidaemia patients 
who were not at goal (as defined by study). MEDLINE, Embase, the Cochrane Library, 
and BIOSIS databases were searched. Guideline publications were searched from 
2008; observational studies were searched from January 2005 to December 2013. 
There were no language or geographical restrictions. Results: 17 guidelines and 
70 observational studies were included in the review. While country-specific guide-
line recommendations vary slightly, the commonly used European Atherosclerosis 
Society and European Society of Cardiology (EAS/ESC) guidelines recommend a 
LDL-C target of < 2.5 mmol/L for patients with high CVD risk. Most studies reported 
that between 61.8% and 95.4% of high-risk patients did not reach this target. 3 
studies from North America reported lower proportions, between 18.9% and 42.3%. 
The EAS/ESC guidelines recommend a LDL-C target of < 1.8 mmol/L for patients 
with very high CVD risk. Studies reported that 68.1% to 96.0% of patients do not 
achieve this goal. ConClusions: Patients in higher cardiovascular-risk categories 
tend to have more stringent LDL-C target levels, which may contribute to failure to 
achieve target levels. This suggests several unmet needs: large numbers of patients 
who fail to achieve LDL-C targets, reducing the patients’ risk for CVD, and conse-
quently reduce the occurrence of cardiovascular events. Based on recently published 
American College of Cardiology and American Heart Association guidelines, which 
do not recommend a treatment target LDL-C level, further research is needed to 
re-evaluate the unmet need in hyperlipidaemia patients.
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objeCtives: Stroke Risk Stratification in AF patients of can be done using 
CHADS2 (Congestive heart failure, Hypertension, Age ≥ 75, DM, prior Stroke/TIA 
[2 points]); or CHA2DS2VASc2 (Congestive heart failure/left ventricular ejection 
fraction ≤ 35%, Hypertension, Age ≥ 75 [2 points], DM, prior Stroke/TIA/thrombo-
embolism [2 points], Vascular disease, Age 65–74, Sex- female). Treatment options 
for Prevention of stroke includes Anti-coagulants (Vitamin K Antagonist-Warfarin, 
Acenocoumarol; and Newer Oral Anticoagulant- Dabigatran) and anti-platelets 
(Aspirin and Clopidogrel). The objective of this study was to assess better tool 
for Stroke Risk Stratification; CHADS2 vs CHA2DS2VASc2 and to observe utiliza-
tion pattern of antithrombotics with stroke as the outcome. Methods: Elderly 
patients (Age> 65yrs) with Non-Valvular Atrial Fibrillation admitted in the hos-
pital within span of 2yrs (2012-13) were selected excluding patients with comor-
bidities like Atrial flutter, DVT, PFO, Endocarditis and/or ARF (after approval of 
ethical committee). Total of 160 patients were segregated based on stroke risk 
and percentage of patients experiencing thromboembolic event in each group 
was observed and CHADS2 and CHA2DS2-VASc were compared. The efficacy of 
antithrombotics in prevention of thromboembolic event in patients with AF was 
studied. Results: For stroke risk stratification, CHA2DS2-VASc was observed to 
be a better tool than CHADS2 to predict ‘truly low risk’, ‘moderate risk’ and ‘high 
risk’ patients. A shift of AF patients from ‘low-moderate risk’ by CHADS2 to ‘high 
risk’ by CHA2DS2VASc was noticed, 95% of patients required anticoagulation (either 
VKA or NOACs) as per CHA2DS2VASc, whereas, only 60% required OACs as per 
CHADS2. Most patients who experienced CVA belonged to ‘No antithrombotics 
prescribed’ group (25%). Dabigatran showed no incidence of CVA outcome, followed 
by VKA-, (Warfarin-28% and Acenocoumarol-18%) and least efficacy was seen by 
